What does the drug do?
Edaravone was originally developed to treat acute ischemic stroke, however it was then tested in people with MND. One theory about why motor neurones die in MND is that they are affected by oxidative stress. Cell’s normal metabolic processes can cause oxidative stress. This can result in cellular damage resulting in excessive accumulation of free radicals. Edaravone acts as a ‘free radical scavenger’ helping to reduce the effects of oxidative stress and hopefully slow the progression of MND.
Phase 3 (ADORE)
The Phase 3 (ADORE) clinical trial is investigating a formulation of oral edaravone, known as FNP122. The trial is randomised, double-blind and placebo controlled. It is aimed to recruit 300 participants with the support of TRICALS, the largest European research initiative to find a cure for ALS. You can find out more about the trial here.
This trial is fully recruited.
Nov 2022 - The trial closed for recruitment.
Nov 2021 - The trial began recruiting in Europe.
Want to find out more about Edaravone? Check out the resources below:
The Scientific Advisory Council (SAC) Briefing Notes
The Scientific Advisory Council for the International Alliance of ALS/MND societies consists of 9 members from USA, UK (including MND Association's Head of Research - Dr Nick Cole), Sweden, Italy, South Africa, China, Australia and Canada.
They produce briefing notes as a trusted source of information about current experimental treatments in clinical development, such as Oral Edaravone.
These notes are produced after many rounds of careful discussion between the SAC members.
You can find the briefing note for Oral Edaravone here.
Last updated: 25/11/2022